AlphAIAlphAI — Financial news for AI agents
tradingview.com$KURA

Weekly Recap: ASH 2026 abstracts accepted and Q3 results due Nov. 10

Kura Oncology (KURA) and Kyowa Kirin had eight ziftomenib abstracts accepted for ASH 2026, including four oral presentations. Kura will report Q3 2026 results on Nov. 10, with expected loss of $0.82 per share and $22.9M revenue. The company granted new hires options for 55,500 shares at $9.79.

Original reporting
tradingview.com
Published Nov 9, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Weekly Recap: ASH 2026 abstracts accepted and Q3 results due Nov. 10 — source image
Source · tradingview.com
Decision brief

The 30-second read

$KURANeutralLow
01

Why it matters

The abstract acceptance signals progress in Kura's pipeline, but the upcoming earnings preview suggests limited immediate upside.

02

Market read

Kura's upcoming earnings and conference activity provide a short-term trading focus for biotech investors.

03

What to watch

Potential for later-stage trial data or partnership announcements not disclosed yet.

Relevance 6/10Novelty 6/10Timing: after market close Nov. 10

Background

Weekly recap summarizing recent biotech news, focusing on Kura Oncology's conference abstracts and upcoming earnings.

Company-level read

Ticker impact

$KURANeutralMedium confidence
Context

Kura Oncology announced eight ziftomenib abstracts accepted for ASH 2026 and will report Q3 results on Nov. 10.

Expected impact

likely downside pressure as analysts expect a loss and modest revenue.

Evidence & confidence

The market anticipates a $0.82 loss per share; abstract acceptance adds modest positive sentiment but does not outweigh earnings expectations.

Market effects

Sector

Highlights ongoing activity in AML drug development, may slightly boost biotech sector interest.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor, confined to niche oncology research community.

Counterpoint

What could challenge this read

Despite abstract acceptance, the expected loss could outweigh any positive sentiment.

Key entities

  • company
    Kura Oncology, Inc.

    US-listed biotech company reporting Q3 results.

  • company
    Kyowa Kirin

    Partner in the abstract submissions.

Read at source← All news

Related articles

$KURAMed

Kura Oncology Q3 Earnings Call Highlights

Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.

finance.yahoo.com
$KURAMed

Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh

SEC EDGAR 8-K
$KURAMedAI 8/10

A leukemia drug’s first results with two other medicines will be presented in December.

Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.

stocktitan.net
$KURAMedAI 8/10

Some rats regained normal blood sugar for a month after an experimental diabetes treatment stopped

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

stocktitan.net